Recent Updates
Recently added Catalysts
CCCC Positive Sentiment

C4 Therapeutics to Participate in Upcoming March Conferences

Monday, February 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: C4 Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two upcoming March conferences. The live webcasts will be accessible on the company's website, with archived replays available for 90 days post-event. C4T focuses on targeted protein degradation to develop new medicines aimed at difficult-to-treat diseases.
Price reaction · baseline $2.16 (2026-02-20 close) · hit pre-market · 1 other CCCC headline(s) in the window, move may be shared
day 0 close
+6.5%
day 1
+10.6%
day 3 · peak
+28.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • C4 Therapeutics is advancing targeted protein degradation science.
  • Management's participation in conferences highlights company visibility.
  • The company's innovative approach may improve patient outcomes.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+31%
120-day peak, hindsight
Typical move
3%
average across 10 past catalysts
Cash runway
~571 mo
Minimal dilution risk
Lead asset
cemsidomide
Phase 2 · Multiple Myeloma

Full Press Release Details

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in two upcoming March conferences.
The live webcasts will be available on the Investors section of the company’s website atwww.c4therapeutics.com. The archived replays of the webcasts will be available for approximately 90 days following the events.
About C4 TherapeuticsC4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO®platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visitwww.c4therapeutics.com.

Contacts:Investors:Courtney SolbergAssociate Director, Investor RelationsCSolberg@c4therapeutics.com

Frequently Asked Questions

What is C4 Therapeutics focused on?

C4 Therapeutics focuses on advancing targeted protein degradation science.

When will the conferences take place?

C4 Therapeutics will participate in two upcoming conferences in March.

How can I access the conference webcasts?

The live webcasts will be available on the Investors section of C4T's website.

How long will the archived webcasts be available?

Archived replays of the webcasts will be available for approximately 90 days.

ShareAdd on Google
Tags: CCCC C4 Therapeutics targeted protein degradation clinical-stage biopharmaceutical
Last updated: Feb 23, 2026

Biotech snapshot

Cash runway
$300M liquidity · $1M/mo burn
~571 mo
Minimal dilution risk
Lead asset
cemsidomidePhase 2
Multiple Myeloma →

Catalyst track record

+31%
best trade around CCCC's most recent catalyst

Peak hindsight return over a 120-day window, across 10 tracked FDA/PDUFA catalysts for CCCC.

See every catalyst's timing & PoA →